Cingulate publishes pharmacokinetic study on ADHD drug candidate By Investing.com
Investing.com Canada
Cingulate has published a pharmacokinetic study regarding its drug candidate for the treatment of Attention Deficit Hyperactivity Disorder. The article reports this development as news from Investing.com Canada without providing specific details about the study's outcomes or data.
All articles from 12 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.